Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. It is available as tablets for oral use. MedsAcross supplies Triazolam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. Triazolam is a benzodiazepine indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults.
Source: US FDA prescribing information
Triazolam is a benzodiazepine. Triazolam exerts its effect for the short-term treatment of insomnia through binding to the benzodiazepine site of the gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Source: US FDA prescribing information
• Adults: Recommended dosage is 0.25 mg once daily before bedtime. Maximum recommended dosage is 0.5 mg once daily. • Geriatric patients: Reduce starting dosage to 0.125 mg once daily. May increase to 0.25 mg if no response. Geriatric patients should not exceed 0.25 mg once daily. • Triazolam should not be prescribed in quantities exceeding a 1-month supply
Source: US FDA prescribing information
Triazolam is contraindicated in: • Patients with known hypersensitivity to triazolam, any of component of triazolam, or other benzodiazepines. Reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. • Concomitant administration of strong cytochrome P450 (CYP 3A) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir). • Known hypersensitivity to triazolam or other benzodiazepines.
Source: US FDA prescribing information
Boxed warning: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. • Persistent or Worsening Insomnia: Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. • "Sleep-driving" and Other Complex Behaviors: Complex behaviors such as "sleep-driving" have been reported.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in greater detail in other sections: • Risks from Concomitant Use with Opioids • Abuse, Misuse, and Addiction • Dependence and Withdrawal Reactions • Persistent or Worsening Insomnia • "Sleep-driving" and Other Complex Behaviors • Central Nervous System Manifestations • Effects on Driving and Operating Heavy Machinery • Patients with Depression • Neonatal Sedation and Withdrawal Syndrome • Compromised Respiratory Function Most common adverse reactions (incidence ≥4% and twice placebo) are drowsiness, dizziness, light-headedness, and coordination disorder/ataxia.
Source: US FDA prescribing information
• Use with Opioids: Increase the risk of respiratory depression. • Use with Other CNS Depressants: Produces additive CNS depressant effects. • Use with CYP 3A4 Inhibitors: Increased risk of adverse reactions
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Triazolam, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Triazolam 0.25 mg tabletOralGeneric name | — | US FDA | Available on request |
| Triazolam 0.125 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 15 November 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Triazolam in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Triazolam and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Triazolam on 15 November 1982, according to Drugs@FDA.
No listed presentation of Triazolam is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Triazolam is classified under ATC code N05CD05 (Triazolam).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.